Front-line Bevacizumab in Serous Epithelial Ovarian Cancer: Biomarker Analysis of the FINAVAST Trial — Anticancer Research

Background: Potential tissue and serum biomarkers were assessed for predicting efficacy of bevacizumab in ovarian cancer (OC).

Conclusion: Our results indicate differences in MMP-9 and HIF-1α expression in relation to duration of PFS (progression free survival) and effects on serum VEGF when bevacizumab (Avastin) is used in combination with chemotherapy.